Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
TE

NASDAQ · TENX

Tenax Therapeutics, Inc.

Healthcare · Biotechnology

$1.84

Up+$0.04 (+2.22%)

Updated Nov 4, 2026, 10:37 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.01M
P/E ratio
-12.4
Dividend yield
0.00%
52-week range
$1.31 – $19.40
Volume
2.5M
Avg. volume
113.76K

Price performance · TENX

TENX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

TENX closed at $1.84 after 21 trading sessions, down 4.66% for the selected period.

Last close
$1.84
Period change
-4.66%
Period low
$1.36
Period high
$1.93
Daily close
View OHLC price history
TENX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.81$1.92$1.79$1.842.5M
Nov 2, 2026$1.83$1.84$1.77$1.801.16M
Oct 30, 2026$1.83$1.85$1.73$1.79888.06K
Oct 29, 2026$1.86$2.01$1.81$1.862.46M
Oct 28, 2026$1.72$1.89$1.6856$1.881.66M
Oct 27, 2026$1.62$1.76$1.60$1.721.67M
Oct 26, 2026$1.72$1.74$1.62$1.641.26M
Oct 23, 2026$1.76$1.76$1.69$1.72854.39K
Oct 22, 2026$1.74$1.8358$1.64$1.763.3M
Oct 21, 2026$1.65$1.70$1.615$1.632.35M
Oct 20, 2026$1.50$1.64$1.50$1.631.46M
Oct 19, 2026$1.41$1.54$1.41$1.522.58M
Oct 16, 2026$1.51$1.52$1.36$1.361.86M
Oct 15, 2026$1.55$1.56$1.51$1.512.01M
Oct 14, 2026$1.60$1.65$1.53$1.5351.96M
Oct 13, 2026$1.84$1.84$1.58$1.607.68M
Oct 12, 2026$1.88$1.88$1.83$1.83790.57K
Oct 9, 2026$1.86$1.91$1.80$1.872.35M
Oct 8, 2026$1.91$1.91$1.825$1.862.41M
Oct 7, 2026$1.92$1.95$1.8902$1.91701.61K
Oct 6, 2026$1.96$1.995$1.90$1.931.18M

Latest TENX news

The latest Smart Investors Daily articles mentioning TENX.

Stock researchCompany · Overview

TENX research

Overview

Company profile and research snapshot.

Company profile

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$20.00
Implied upside
—
Analysts
—
TENX recent ratings
DateFirmRatingTarget
Aug 31, 2026GuggenheimNeutral—
Aug 11, 2026Canaccord GenuityBuy—
Aug 11, 2026Chardan CapitalNeutral—
Aug 11, 2026GuggenheimBuy—
Aug 11, 2026Evercore ISI GroupIn-Line—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Tenax Therapeutics (TENX) Stock Fair Value Falls After Cautious Analyst Calls On LEVEL Data

The latest analyst update on Tenax Therapeutics trims the fair value estimate from US$12.56 to US$9.63, a reduction of about 23% in the modeled price target. This cut lines up with more cautious Street commentary after the LEVEL Phase 3 results, as research desks weigh potential value in PH-HFpEF subgroups against execution and financing questions. Read on to see how this evolving narrative may shape how you track Tenax Therapeutics from here. Stay updated as the Fair Value for Tenax...

Yahoo · Sep 4, 2026

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By